Who
Mark Stejbach
Director
Company insider
Files Form 4 as: Director, Indivior Pharmaceuticals; Director, Flexion Therapeutics; SVP/Chief Comm Off, Alks Inc, Alkermes; VP and Chief Commercial Offcr, Tengion.
In numbers
- Trades disclosed
- 129
- Buys
- 5
- Sells
- 9
- Bought
- $126K
- Sold
- $5.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 9 Apr 2010
- Last trade
- 13 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 14 May 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,518 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,518 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,722 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,722 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $27K775 at $35.39 | filing |
| 5 Jan 2026filed 7 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $27K775 at $35.39 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,000 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,000 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Flexion Therapeutics | SEC FORM 4 Code D | $107K12,631 at $8.50 | filing |
| 24 Jun 2021filed 28 Jun 2021 | Flexion Therapeutics | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 24 Jun 2021filed 28 Jun 2021 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 10 Jun 2020filed 12 Jun 2020 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 10 Jun 2020filed 12 Jun 2020 | Flexion Therapeutics | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 26 May 2020filed 27 May 2020 | Flexion Therapeutics | SEC FORM 4 Bought | $20K2,051 at $9.75 | filing |
| 19 Jun 2019filed 21 Jun 2019 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 20 Jun 2018filed 21 Jun 2018 | Flexion Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
News
Contrasting Orion OYJ (OTCMKTS:ORINY) & Indivior (NASDAQ:INDV)INDV · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Mark Stejbach; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.